Hiroaki Mitsuya
HIV and AIDS Malignancy Branch
The Center for Cancer Research
United States of America
Biography
Dr. Hiroaki Mitsuya obtained his M.D. and Ph.D. in Kumamoto University School of Medicine in Japan. After receiving immunology/hematology/oncology training at Kumamoto University Hospital, Dr. Mitsuya joined the National Cancer Institute in 1982 and began studying the outcomes of infection by human T cell leukemia virus type 1, the first known human pathogenic retrovirus. In 1984, Dr. Mitsuya steered his attention to human immunodeficiency virus or HIV. In 1985, he identified three nucleoside reverse transcriptase inhibitors (NRTIs: 3'-azido-2',3'-dideoxythymidine or AZT, 2',3'-dideoxyinosine or ddI, and 2',3'-dideoxycytidine or ddC) now widely used in the treatment of acquired immunodeficiency syndrome (AIDS), and guided much of their preclinical development. Dr. Mitsuya has been chief of the Experimental Retrovirology Section since 1991.
Research Interest
Molecular Pharmacology, Virology
Publications
-
Yamaguchi S, Iwanaga E, Tokunaga K, Nanri T, Shimomura T, et al. (2014) IDH1 and IDH2 mutations confer an adverse effect in patients with acute myeloid leukemia lacking the NPM1 mutation. Eur. J. Haematol. 92: 471-7.
-
Matsuzawa T, Kawamura T, Ogawa Y, Maeda K, Nakata H, et al. (2014) EFdA, a reverse transcriptase inhibitor, potently blocks HIV-1 ex vivo infection of Langerhans cells within epithelium. J. Invest. Dermatol. 134: 1158-61.
-
Yedidi RS, Garimella H, Aoki M, Aoki H, Desai DV, et al. (2014) Conserved hydrogen-bonding network of P2 bis-tetrahydrofuran containing HIV-1 protease inhibitors (PI) with protease active site amino acid-backbone aid in their activity against PI-resistant HIV. Antimicrob. Agents Chemother. 58: 3679-88.
